中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
8期
88-89
,共2页
灯盏花素%骨性关节炎%玻璃酸钠
燈盞花素%骨性關節炎%玻璃痠鈉
등잔화소%골성관절염%파리산납
breviscapine%osteoarthritis%sodium hyaluronate
目的：观察灯盏花素治疗膝关节骨性关节炎的临床疗效。方法选取医院2012年1月至2013年3月收治的膝关节骨性关节炎患者90例，按入院先后顺序随机分为两组，各45例。两组患者均采用关节腔给药疗法，观察组患者采用灯盏花素注射液，对照组患者采用玻璃酸钠注射液。比较两组患者治疗前后Lysholm膝关节的功能评分、视觉模拟评分法（VAS）评分，并评价疗效。结果观察组总有效率为95.56%，明显高于对照组的77.78%（χ2=5.47，P＜0.05）；两组患者治疗后Lysholm评分均显著升高（ P＜0.05），VAS评分均显著降低（ P＜0.05），组间比较，差异均有统计学意义（ P＜0.05）；两组患者均未见明显的全身不良反应，且均未发生感染。结论灯盏花素关节腔给药治疗膝关节骨性关节炎更能缓解疼痛，改善关节功能，且不良反应少，值得临床推广。
目的：觀察燈盞花素治療膝關節骨性關節炎的臨床療效。方法選取醫院2012年1月至2013年3月收治的膝關節骨性關節炎患者90例，按入院先後順序隨機分為兩組，各45例。兩組患者均採用關節腔給藥療法，觀察組患者採用燈盞花素註射液，對照組患者採用玻璃痠鈉註射液。比較兩組患者治療前後Lysholm膝關節的功能評分、視覺模擬評分法（VAS）評分，併評價療效。結果觀察組總有效率為95.56%，明顯高于對照組的77.78%（χ2=5.47，P＜0.05）；兩組患者治療後Lysholm評分均顯著升高（ P＜0.05），VAS評分均顯著降低（ P＜0.05），組間比較，差異均有統計學意義（ P＜0.05）；兩組患者均未見明顯的全身不良反應，且均未髮生感染。結論燈盞花素關節腔給藥治療膝關節骨性關節炎更能緩解疼痛，改善關節功能，且不良反應少，值得臨床推廣。
목적：관찰등잔화소치료슬관절골성관절염적림상료효。방법선취의원2012년1월지2013년3월수치적슬관절골성관절염환자90례，안입원선후순서수궤분위량조，각45례。량조환자균채용관절강급약요법，관찰조환자채용등잔화소주사액，대조조환자채용파리산납주사액。비교량조환자치료전후Lysholm슬관절적공능평분、시각모의평분법（VAS）평분，병평개료효。결과관찰조총유효솔위95.56%，명현고우대조조적77.78%（χ2=5.47，P＜0.05）；량조환자치료후Lysholm평분균현저승고（ P＜0.05），VAS평분균현저강저（ P＜0.05），조간비교，차이균유통계학의의（ P＜0.05）；량조환자균미견명현적전신불량반응，차균미발생감염。결론등잔화소관절강급약치료슬관절골성관절염경능완해동통，개선관절공능，차불량반응소，치득림상추엄。
Objective To investigate the clinical effect of breviscapine in treating knee osteoarthritis. Methods Totally 90 cases of knee osteoarthritis admitted to the hospital from January 2012 to March 2013 were selected and randomly divided into two groups according to the admission sequence,45 cases in each group. The two groups were all treated with the intra-articular injection therapy. The ob-servation group used Breviscapine Injection,while the control group was given Sodium Hyaluronate Injection. The Lysholm knee function scores and the VAS scores before and after treatment were compared between the two groups and the clinical efficacy was evaluated. Results The total effective rate of the observation group was 95. 56%,which was significanty higher than 77. 78% in the control group(χ2=5. 47,P < 0. 05). The Lysholm scores after treatment in the two groups were increased significantly( P < 0. 05) and the VAS scores were decreased significantly( P < 0. 05). Comparison between the two groups showed statistical difference( P < 0. 05). There was no obvious systemic adverse reactions in the two groups,moreover no infection occurred. Conclusion Breviscapine by intra-articular injection in treating osteoarthritis can relieve pain,improve the joint function,has fewer adverse reactions,and is worthy of clinical promotion.
